Audit Ready eIFU Translation for Regulatory Teams: AD VERBUM AI+Human
eIFU translation must run through a traceable, ISO-aligned workflow that enforces terminology control and requires subject-matter expert sign-off before publication. The immediate next step is exporting your master source files, translation memories, and term bases so every language version originates from the same controlled content. Skipping that step is the single most common reason eIFU translations fail regulatory review.
Table of Contents
Regulatory Requirements That Shape eIFU Translation and Publishing
The Step-By-Step eIFU Translation Workflow That Holds Up in an Audit
Platform Features That Determine Whether Translated eIFUs Stay Compliant
Translation Failure Modes That Cause Real Patient Safety Incidents
Why Most Teams Underestimate the Governance Problem, Not the Language Problem
Your Immediate Checklist Before Starting an eIFU Translation Project
What Counts as an eIFU and Which Content Must Be Translated
An electronic Instructions for Use (eIFU) is a digitally delivered version of a device’s instructions, typically served as a tagged PDF, structured HTML page, or a multimedia asset with captions, replacing or supplementing the paper insert. The format matters for translation because each asset type carries different localization mechanics: PDFs need layout-aware desktop publishing (DTP) after translation, HTML needs string-level extraction that preserves markup, and video captions need timing-synced subtitle files rather than flat text.
Scope depends heavily on device classification. Devices intended for professional healthcare use in institutional settings can often go eIFU-only under Commission Implementing Regulation (EU) 2021/2226, while devices intended for lay users, home use, or implantable devices generally still require a paper IFU alongside any digital version.
Certain sections demand tighter controls than the rest of the document, regardless of format:
Warnings and contraindications, where a single dropped negation changes the clinical meaning
Dosing, measurements, and unit conversions, where a misplaced decimal is a patient safety event
Stepwise procedural instructions, where sequence errors affect device function
Symbol glossaries and legends, which must match harmonized terminology across all language versions
Regulatory Requirements That Shape eIFU Translation and Publishing
Regulation (EU) 2017/745 (EU MDR) sets the baseline: Article 8 requires that instructions for use be available and accurate, and individual EU member states set their own language requirements for the markets where a device is sold. That means an eIFU program is not a single translation job. It is a matrix of language obligations tied to every country where the device ships.
Commission Implementing Regulation (EU) 2021/2226 narrows the paper exemption to defined device categories, mainly professional-use and installed equipment, and it attaches technical strings to that exemption: manufacturers need version control, language switching, and accessibility support on the publishing platform itself. Eliminating paper does not eliminate obligation. It shifts the obligation onto the software.
In the United States, the FDA’s general labeling requirements do not mandate specific languages, but they require labeling to be truthful and not misleading. When a manufacturer chooses to provide translated instructions for a US market, the FDA’s device labeling guidance (G91-1) applies the same adequacy standard to the translated content that it applies to the English original. A translation that softens a warning or drops a contraindication is a labeling violation, not a linguistic quirk.
Auditors and notified bodies reviewing an eIFU program will typically check:
Version control records tying each published language to a specific approved source revision
Audit trails showing who translated, reviewed, and approved each language version, and when
Documented qualifications for translators and subject-matter expert (SME) reviewers on the project
Computer system validation (CSV) evidence for the platform that publishes and serves the translated eIFUs
Traceability between the terminology used in the translation and the approved term base or glossary
The Step-By-Step eIFU Translation Workflow That Holds Up in an Audit
Asset integration comes first, always. Import the client’s existing translation memory ™ and term base (TB) before any new translation work starts. Reusing approved terminology from prior regulatory submissions cuts inconsistency risk and gives reviewers a documented baseline to check new segments against.
Set explicit rules for automated output before generation begins. Large language model (LLM) or machine translation (MT) systems can accelerate first-pass drafting, but only when constrained by the client’s TM and TB rather than left to generate freely. For the highest-risk segments, contraindications, dosing, and warning statements, many regulated teams choose to route those lines directly to human translation and skip automated drafting entirely, treating the constrained output as a starting point for SME review rather than a final answer anywhere near a safety claim.
Certified SME review follows generation, with a checklist, not a skim. Reviewers with clinical or technical domain background should verify, segment by segment: numeric values and units, negation and modal verbs (must, may, should), warning severity language, and consistency with the approved glossary. This step catches the errors that generic linguistic review misses because it takes a translator with device or clinical knowledge to recognize when a technically fluent sentence is clinically wrong.
Linguistic QA and accessibility remediation come next. This stage covers grammar, register, and in-country readability, followed by DTP for PDF layouts and accessibility remediation for tagged text, alt text on diagrams, and caption files for video content. Sign-off at this stage should be a named, logged approval, not an informal “looks good.”
Publication closes the loop, with full metadata. The final translated eIFU goes live on the publishing platform with version numbering, a stable URL or QR code per language, and complete audit metadata: source revision, translator and reviewer identity, approval date, and change history. If a regulator asks which version of the German IFU was live on a given date, the platform should answer that in seconds, not after a records search.
QA, ISO Alignment, and the Evidence Package Auditors Expect
Three ISO standards map directly onto eIFU translation quality expectations. ISO 17100 sets requirements for the translation process itself, including translator qualifications and a mandatory second-linguist revision step. ISO 18587 governs post-editing when machine-generated output feeds into the workflow, specifying what a qualified post-editor must check before that output is treated as final. ISO 13485 covers quality management for medical device manufacturers and extends, in practice, to how they control documentation, including translated labeling and IFUs, as part of their broader quality system.
An eIFU publishing platform, because it is a regulated computer system, needs computer system validation (CSV) evidence: a User Requirements Specification (URS), Installation and Operational Qualification (IQ/OQ), Performance Qualification (PQ), and change-control logs documenting every update to the platform’s functionality. A validated platform reduces day-to-day translation friction, but the validation package itself still has to exist as a produced, reviewable artifact.
Terminology governance ties the two together. Every decision about how to translate a specific device term, a warning phrase, or a unit convention should be recorded, dated, and attributed, not left as tribal knowledge in a translator’s head.
At minimum, an evidence package for regulatory review should include the approved TM/TB versions used, SME reviewer credentials, the CSV validation summary, and the full audit log for the published languages under review.
Platform Features That Determine Whether Translated eIFUs Stay Compliant
Version control needs a stable URL or QR code per device, with a distinct, logged record for every published language. Change the source content and every downstream language version needs its own tracked update, not a silent overwrite.
Language handling on the platform matters as much as the translation itself:
Automatic language serving based on browser or region settings, with a manual language selector as fallback
Accessibility features including tagged PDFs, alt text for diagrams, and transcripts for any video instructions, per platform feature standards
A linked accessibility statement describing how users with disabilities can request an alternative format
Paper-on-request handling that stays compliant with MDR labeling obligations even when the default distribution is digital
Labels that carry a URL or QR code to the eIFU need durable platform infrastructure behind them. A broken link or an unversioned page defeats the purpose of the exemption that let the manufacturer skip paper in the first place.
Translation Failure Modes That Cause Real Patient Safety Incidents
Unit and decimal errors top the list: a translator working across metric and imperial systems, or shifting a decimal separator convention between locales, can turn a safe dose into a dangerous one. Negation loss is close behind, where “do not exceed” becomes “exceed” through a dropped word or a mistranslated modal verb, a risk that ungoverned machine translation makes more likely without human oversight. Omitted contraindications happen when a translator or reviewer treats a warning section as boilerplate and skims past it.
Detection needs to be built into the workflow, not bolted on afterward. Targeted SME checklists for numeric segments, bilingual QA comparing source and target sentence by sentence on warning language, and regression testing against the approved TM all catch these errors before publication.
Mitigation comes down to three controls: enforce terminology through the TB rather than trusting translator memory, deliberately stress-test the highest-risk warning statements with a second independent reviewer, and require documented clinical sign-off before any safety-critical segment goes live.
Case Studies in eIFU Translation: What Actually Went Right
A multinational diagnostics manufacturer moving a professional-use analyzer’s IFU to eIFU-only status under the EU exemption ran into a problem common to that transition: its existing paper IFU translations had never been indexed into a shared term base, so each new language project started from near zero. Rebuilding the TB from the approved paper translations before starting new eIFU work cut review cycles substantially because reviewers were checking against an approved reference instead of arbitrating fresh terminology choices for every device family.
Another recurring pattern shows up in orthopedic implant manufacturers publishing eIFUs across all required EU languages simultaneously. Teams that assigned a single SME reviewer per language, rather than rotating reviewers between projects, caught unit and dosing inconsistencies faster because that reviewer built familiarity with the device family’s specific risk language over multiple release cycles.
The lesson across both cases is the same: eIFU translation quality tracks the durability of the terminology and reviewer assignments behind it, not the speed of any single translation pass.
Why Most Teams Underestimate the Governance Problem, Not the Language Problem
The conventional wisdom treats eIFU translation as a language quality problem: find good translators, get good output. That framing misses where most compliance failures actually originate, which is governance, not grammar.
A fluent, natural-sounding translation can still be a labeling violation if nobody can prove who approved it, when the source content last changed, or whether the terminology matches the device’s approved glossary. Regulators reviewing a technical file after an adverse event care less about elegant phrasing and more about whether the manufacturer can reconstruct the exact chain of custody for a specific warning statement in a specific language on a specific date.
That is why AI-assisted drafting, when properly constrained, is not the risk factor critics assume it is. The risk factor is unconstrained automation with no terminology enforcement and no mandatory SME checkpoint, whether that automation is a public MT engine or a human translator working from memory instead of an approved glossary. The fix in both cases is identical: control the inputs, mandate the review, log the decision. Teams that build that discipline into their process tend to spend less time firefighting during audits, because the evidence they need already exists in the workflow rather than needing to be reconstructed after the fact.
— Eric Brown
Preparing an eIFU Translation Request With AD VERBUM
eIFU translation is run through an AI+HUMAN hybrid workflow built specifically for regulated content: translation memories and term bases go in first, a proprietary system generates a constrained first pass, and a subject-matter expert reviews every safety-relevant segment before QA aligned to ISO 17100 and ISO 18587 closes the file. The system runs on EU-hosted infrastructure, which matters for manufacturers who need data sovereignty guarantees alongside translation quality.
To request a quote, prepare your master source files, existing TM/TB exports, the target language list, and the scope of any CSV documentation you already hold. A language service team can scope the project against your existing regulatory file rather than starting from a blank terminology set. For related localization needs beyond the IFU itself, from multilingual product listings to compliant regional content, the multilingual SEO and LLMO services page covers adjacent language work, and the full services overview lists regulated translation offerings available.
Your Immediate Checklist Before Starting an eIFU Translation Project
Before any translation work begins, get these items in hand:
Export current TMs and TBs for every target language already in use
Assign a named SME reviewer with clinical or technical background per device family
Request CSV documentation (URS, IQ/OQ/PQ) from your eIFU publishing platform vendor
Draft or update the accessibility statement linked from each published eIFU
Confirm version control and audit logging are active before the first language goes live
Your minimum evidence package for regulatory review needs the approved TM/TB versions, SME credentials, the CSV validation summary, and a complete audit trail. Warnings and contraindications get priority review in every language, every time, with no exceptions for tight deadlines.
Sources
The regulatory claims in this guide draw on Regulation (EU) 2017/745 for EU MDR baseline obligations, Commission Implementing Regulation (EU) 2021/2226 for the eIFU-only exemption criteria, and the FDA’s general device labeling requirements for US labeling adequacy standards. Platform feature expectations reference MDIS eIFU management documentation, which auditors and manufacturers use to benchmark version control and accessibility capability. Each source addresses a distinct piece of the compliance chain: what must be translated, when paper can be skipped, and what a publishing platform must prove it can do.
Recommended
